Global News

[ad_1] A messy legal fight over the Food and Drug Administration's approval of the abortion pill mifepristone poses risks to the biopharma industry that go beyond the single drug. If a subsequent decision tosses out the pill's approval, it could potentially stifle innovation in the sector and deter investments in the development of life-changing drugs, biopharma companies and experts in law and economics say.  related investing news The ruling Friday by U.S. District Judge Matthew Kacsmaryk of Amarillo, Texas, appears to be the first time a court has suspended the FDA's approval of a medication. The 5th U.S. Circuit Court of Appeals late Wednesday partly granted the Biden administration's request to put the order on hold, making mifepristone available for now but with significant restrictions .  The Justice Department will seek emergency intervention from the U.S. Supreme Court, it said Thursday. Nationwide access to mifepristone still hangs in the balance as the

[ad_1] An investigation into the leak of a bombshell Supreme Court ruling overturning the federal constitutional right to abortion — weeks before it was officially released — failed to identify the culprit, the court said Thursday. The failure to find the source of the leak was yet another embarrassing development for the Supreme Court, which on Thursday called the leak "one of the worst betrayals of trust in its history" and "a grave assault on the judicial process." Politico in May reported that a leaked draft opinion written by Justice Samuel Alito showed that the Supreme Court was poised to overturn its five-decade-old ruling in the case known as Roe v. Wade, which found there was a constitutional right to abortion. In June, just as the leak report suggested, the Supreme Court in a majority opinion penned by the conservative Alito said there was no federal right to abortion. On the heels of the leak, Chief Justice John Roberts directed Gail Curley, the m